Anchiano Therapeutics Ltd. - American Depositary Share (ANCN): Price and Financial Metrics

Anchiano Therapeutics Ltd. - American Depositary Share (ANCN): $75.36

3.84 (+5.37%)

POWR Rating

Component Grades













Add ANCN to Watchlist
Sign Up

Industry: Biotech



in industry

ANCN Stock Price Chart Interactive Chart >

Price chart for ANCN

ANCN Price/Volume Stats

Current price $75.36 52-week high $131.20
Prev. close $4.47 52-week low $0.51
Day low $73.60 Volume 1,564,843
Day high $131.20 Avg. volume 3,145,648
50-day MA $3.26 Dividend yield N/A
200-day MA $1.79 Market Cap 559.17M

Anchiano Therapeutics Ltd. - American Depositary Share (ANCN) Company Bio

Anchiano Therapeutics Ltd. is a clinical-stage biopharmaceutical company, which engages in tin the discovery, development and commercialization of drugs for cancer-related diseases. Its products include two drugs for cancer BC-819 and BC-821. The company was founded by Avraham Hochberg in 2004 and is headquartered in Jerusalem, Israel.

ANCN Latest News Stream

Event/Time News Detail
Loading, please wait...

ANCN Latest Social Stream

Loading social stream, please wait...

View Full ANCN Social Stream

Latest ANCN News From Around the Web

Below are the latest news stories about Anchiano Therapeutics Ltd that investors may wish to consider to help them evaluate ANCN as an investment opportunity.

Anchiano shares rally 76% on Chemomab merger approval, secures $45.5M capital raise

Anchiano Therapeutics (ANCN) soars 76% after-hours as its shareholders voted to approve the contemplated merger with Chemomab and the issuance of Anchiano ADSs in connection with the pending merger.Shareholders also approved a reverse split of ANCN's common shares, expected to take effect immediately prior to the closing of the merger. The combined company is...

Seeking Alpha | March 16, 2021

ANCN Stock: 10 Things to Know as Anchiano Therapeutics Rockets Higher

ANCN stock is an early-stage company engaged in clinical trials for rare liver, lung and skin diseases with no FDA-approved options now.

InvestorPlace | February 10, 2021

ANCHIANO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of Anchiano Therapeutics Ltd. - ANCN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ("KSF") are investigating the proposed merger of Anchiano Therapeutics Ltd. (NasdaqGS: ANCN) with Chemomab Ltd. pursuant to which Anchiano shareholders will end up owning only approximately 10% of the combined company, prior to additional PIPE financing. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger undervalues the Company.

Yahoo | February 9, 2021

SHAREHOLDER ALERT: WeissLaw LLP Reminds CPAH, CATM, ANCN and GNBF Shareholders About Its Ongoing Investigations

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Yahoo | January 28, 2021

SHAREHOLDER ALERT: Rigrodsky Law, P.A. Reminds Investors of Investigations of ANCN, JWS, GXGX, and ALSK Mergers

WILMINGTON, Del., Jan. 26, 2021 (GLOBE NEWSWIRE) -- Rigrodsky Law, P.A. announces that it is investigating: Anchiano Therapeutics Ltd. (NASDAQ GS: ANCN) regarding possible breaches of fiduciary duties and other violations of law related to Anchiano Therapeutics’ agreement to merge with Chemomab Ltd. To learn more about this investigation and your rights, visit: Jaws Acquisition Corp. (NYSE: JWS) regarding possible breaches of fiduciary duties and other violations of law related to Jaws Acquisition’s agreement to merge with Cano Health, LLC. To learn more about this investigation and your rights, visit: GX Acquisition Corp. (NASDAQ GS: GXGX) regarding possible breaches of fiduc...

Yahoo | January 26, 2021

Read More 'ANCN' Stories Here

ANCN Price Returns

1-mo N/A
3-mo N/A
6-mo N/A
1-year N/A
3-year 499.24%
5-year N/A
2022 N/A
2021 0.00%
2020 23.57%
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6932 seconds.